- Home
- AMGN vs MU Comparison
AMGN vs MU Comparison
Compare AMGN & MU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- MU
- Stock Information
- Founded
- AMGN 1980
- MU 1978
- Country
- AMGN United States
- MU United States
- Employees
- AMGN N/A
- MU N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- MU Semiconductors
- Sector
- AMGN Health Care
- MU Technology
- Exchange
- AMGN Nasdaq
- MU Nasdaq
- Market Cap
- AMGN 157.5B
- MU 135.3B
- IPO Year
- AMGN N/A
- MU N/A
- Fundamental
- Price
- AMGN $292.51
- MU $120.11
- Analyst Decision
- AMGN Hold
- MU Strong Buy
- Analyst Count
- AMGN 20
- MU 27
- Target Price
- AMGN $322.30
- MU $152.11
- AVG Volume (30 Days)
- AMGN 2.7M
- MU 25.8M
- Earning Date
- AMGN 08-05-2025
- MU 06-25-2025
- Dividend Yield
- AMGN 3.25%
- MU 0.38%
- EPS Growth
- AMGN 56.16
- MU N/A
- EPS
- AMGN 10.94
- MU 5.50
- Revenue
- AMGN $34,126,000,000.00
- MU $33,813,000,000.00
- Revenue This Year
- AMGN $7.73
- MU $50.60
- Revenue Next Year
- AMGN $1.78
- MU $30.79
- P/E Ratio
- AMGN $26.78
- MU $21.87
- Revenue Growth
- AMGN 15.56
- MU 58.22
- 52 Week Low
- AMGN $253.30
- MU $61.54
- 52 Week High
- AMGN $346.85
- MU $135.35
- Technical
- Relative Strength Index (RSI)
- AMGN 52.53
- MU 54.58
- Support Level
- AMGN $291.25
- MU $117.02
- Resistance Level
- AMGN $302.38
- MU $124.81
- Average True Range (ATR)
- AMGN 7.04
- MU 3.54
- MACD
- AMGN 0.55
- MU -1.49
- Stochastic Oscillator
- AMGN 66.26
- MU 24.08
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.